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Abstract
Immunotherapy using regulatory T cells (Treg) has been proposed, yet cellular and molecular mechanisms of human Tregs
remain incompletely characterized. Here, we demonstrate that human Tregs promote the generation of myeloid dendritic
cells (DC) with reduced capacity to stimulate effector T cell responses. In a model of xenogeneic graft-versus-host disease
(GVHD), allogeneic human DC conditioned with Tregs suppressed human T cell activation and completely abrogated
posttransplant lethality. Tregs induced programmed death ligand-1 (PD-L1) expression on Treg-conditioned DC;
subsequently, Treg-conditioned DC induced PD-L1 expression in vivo on effector T cells. PD-L1 blockade reversed Treg-
conditioned DC function in vitro and in vivo, thereby demonstrating that human Tregs can promote immune suppression
via DC modulation through PD-L1 up-regulation. This identification of a human Treg downstream cellular effector (DC) and
molecular mechanism (PD-L1) will facilitate the rational design of clinical trials to modulate alloreactivity.
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Introduction
Regulatory T cells (Tregs) promote immune tolerance to self-
antigens and alloantigens (reviewed in [1]). Genetic deficiency of
Tregs mediated by lack of Foxp3 transcription factor yields
autoimmunity in mice [2] and humans [3]. Numerical or functional
deficiency of Tregs in murine models exacerbates autoimmune
disease [4,5], predisposes to solid organ and hematopoietic stem cell
graft rejection [6,7], and associates with acute and chronic graft-
versus-host disease (GVHD) [8–10]. Importantly, clinical studies
have demonstrated Treg defects in humans with autoimmune
disease [11,12] and GVHD [13–15]. Given this background, a
rationale has been outlined to evaluate adoptive cell therapy using
ex vivo–expanded Tregs as an approach to treat autoimmune [16]
or alloimmune [17] conditions. Negative selection against the IL-7
receptor alpha chain (CD127) enriches for human Tregs [18] and
thereby may represent a useful tool for such cell therapy efforts;
however, there are currently no reports pertaining to the regulatory
function of cells expanded from CD127-depleted human T cells.
Given this information, our experiments focused on human Tregs
generated ex vivo by enrichment for CD127-depleted CD4
+ Tc e l l s
and by culture in conditions demonstrated to promote Treg
expansion, including CD28 costimulation IL-2, TGF-b [19], and
rapamycin [20].
A more comprehensive understanding of cellular and molecular
mechanisms of adoptively transferred Treg products would
facilitate the rational design of clinical trials evaluating Tregs.
Such an understanding may be difficult to ascertain given the
varieties of Tregs [21] and numerous molecular mechanisms
operational in murine Treg cells, including: CTLA-4 [22], TGF-b
[23], PD-L1 [24], GITR [25], or IL-10 [9]. The cellular
mechanism of Tregs also is complex and varied depending on
the particular experimental model; importantly, recent evidence
indicates that murine Tregs inhibit responder T cells indirectly via
modulation of dendritic cells (DC) [26,27].
Identification of cellular and molecular mechanisms of
human Tregs, in particular ex vivo–generated Tregs, has been
relatively elusive. For example, ex vivo–generated human Tregs
suppressed an allogeneic mixed lymphocyte reaction (allo-
MLR) by an undefined mechanism that operated independent
of IL-10 or TGF-b [28]. Indeed, the role of antigen-presenting-
cell (APC) modulation as a human Treg mechanism has been
somewhat neglected in part because published studies have
typically utilized APC-free suppressor assays. Nonetheless, one
recent study determined that freshly isolated Tregs inhibited
myeloid DC inflammatory cytokine secretion and costimulatory
molecule expression; such Treg-conditioned DC had reduced
capacity to stimulate alloreactivity in vitro [29]. In light of this
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vivo–generated human Tregs, our primary objective was to
elucidate the cellular and molecular pathways associated with
human Treg cell suppressor function. Because of our focus on
allogeneic hematopoietic stem cell transplantation (HSCT), the
role of Tregs in GVHD protection, and the role of host APC for
GVHD induction [30], we elected to study human Tregs in
vitro using an allo-MLR driven by a defined population of
myeloid DC and in vivo using a xenogeneic GVHD (x-GVHD)
model similar to that previously utilized to study human Tregs
[31].
Results
CD127 Negative Selection and Expansion Yields a Human
Treg Phenotype
Total CD4
+ and CD4
+CD127
2 T cells were costimulated and
expanded in medium containing IL-2, TGF-b1, and rapamycin to
generate control bulk ‘‘CD4’’ and ‘‘Treg’’ populations that were
directly compared in each experiment. Expanded T cells
maintained their CD127
2 status, were comparable in terms of
expansion (Figure S1A), coexpression of CD62L with CCR7
(Figure S1B (i)) and Foxp3 expression (Figure S1B (ii)). Because
Foxp3 is expressed in human Tregs and transiently expressed in
human effector T cells [32], we reasoned that bulk CD4 cell Foxp3
content may represent a marker of effector differentiation. To
address this, we compared ex vivo–expanded T cells for
simultaneous expression of Foxp3 and effector cytokines, including
IL-2 (Foxp3
+IL-2
+ events) and IFN-c (Foxp3
+IFN-c
+ events).
Indeed, relative to Tregs, control CD4 cells had increased
coexpression of Foxp3 with IL-2 (Figure S1C (i)) and Foxp3 with
IFN-c (Figure S1C (ii)). Furthermore, relative to control CD4 cells,
expanded Tregs mediated increased suppression of CD4
+ and
CD8
+ T cell alloreactivity (Figure S1D (i) and S1D (ii));
suppression was observed at a Treg cell to responder T cell ratio
of 1:20 that approximates the physiologic ratio (see dose-response
curve, Figure S1E).
Treg Cells Modulate the Programmed Death-1 (PD-1)
Pathway
Further experiments were performed to characterize the
mechanism of immune modulation mediated by expanded Tregs
generated from CD4
+CD127
2 cells. Blockade of TGF-b, IL-10,
IDO, CTLA4, or LAP did not abrogate Treg suppression in the
allo-MLR (unpublished data). However, experiments utilizing
transwell plates indicated that Treg suppression in the allo-MLR
was contact dependent (unpublished data). Programmed death
(PD) ligand 1 (PD-L1, or B7-H1) is expressed on DC [33], human
tumor cells [34], and normal human tissue [35] and interacts with
PD receptors on T cells to modulate the balance of tolerance and
immunity (reviewed in [36]). In murine systems, Treg cell
expression of PD-L1 associates with suppressor function [24]; in
addition, endothelial cell [37] or CD8a
+ DC [38] expression of
PD-L1 promotes murine Treg generation. In humans, intratumor
Tregs directly inhibited responder T cell proliferation through PD-
L1 [39]. Because Tregs in our experiments expressed increased
PD-L1 (Figure 1A; representative flow plot (i) and (ii); summary
(iii)), we reasoned that Tregs might modulate DC via the PD-1
pathway. Indeed, allogeneic DC isolated from the Treg-containing
MLR expressed increased PD-L1 relative to DC isolated from the
standard MLR (Figure 1B; representative plot (i) and (ii); summary
(iii)); remarkably, DC harvested from control CD4-containing
MLR failed to up-regulate PD-L1. Of note, Treg-conditioned
DC did not have increased expression of PD-1 (CD11c
+PD-1
+
cells, ,1%).
PD-L1 inhibits T cell function via the PD-1 receptor and B7-1
(CD80) [40]. To determine PD-L1 binding pathways in our
system, we first measured effector T cell expression of PD-1 and
CD80 after incubation with three types of allogeneic myeloid DC
(control, Treg conditioned, or control CD4 conditioned). Effector
CD4
+ T cells (Figure 1C; representative flow plot (i)and (ii);
summary (iii)) and CD8
+ T cells (Figure 1C representative flow
plot (iv) and (v); summary (vi)) up-regulated PD-1 expression, but
not CD80 expression, upon exposure to Treg-conditioned DC, but
not CD4-conditioned DC. We next utilized a PD-L1 fusion
protein to characterize binding pathways. Using laser scanning
cytometry (LSC), we found that effector T cells up-regulated total
PD-L1 binding partners in the presence of Treg-conditioned DC,
but not CD4-conditioned DC (Figure 1D, left panel); importantly,
effector T cell PD-L1 binding was abrogated by T cell
preincubation with anti-PD1, but not anti-CD80 (Figure 1C, right
panel). And finally, effector T cell PD-L1 binding was quantified
by flow cytometry (Figure 1E (i)–(iii)). Remarkably, PD-L1 binding
was greatly increased on effector T cells exposed to Treg-
conditioned DC (% effector T cell PD-L1 binding increased from
7.360.4 to 92.662.8, p=0.001); similar to results using LSC,
effector T cell PD-L1 binding was abrogated by T cell
preincubation with anti-PD1, but not anti-CD80 (Figure 1E (iv)).
Allogeneic DC Conditioned with Tregs Possess Reduced
Allostimulatory Capacity
Secondary transfer experiments were performed to evaluate
whether Tregs mediated suppression in part through DC
modulation (experimental scheme, Figure 2A). Indeed, allogeneic
DC conditioned with Tregs yielded reduced levels of CD4
+ and
CD8
+ responder T cell proliferation relative to CD4-conditioned
allogeneic DC (representative results, Figure 2B; pooled results,
Figure 2C). Importantly, blockade of DC expression of PD-L1
partially corrected the observed stimulatory deficit of Treg-
conditioned DC on CD4
+ and CD8
+ T cell proliferation
(representative results, Figure 2B; pooled results, Figure 2C).
Author Summary
Graft-versus-host disease (GVHD) is the most serious
complication of bone marrow transplants between
individuals (so-called allogenic transplants). The class of
suppressor immune cells called regulatory T cells (Tregs)
inhibit GVHD by dampening the effects of donor
immune cells in the grafted tissue. The cellular and
molecular mechanisms involved in this process have not
been fully characterized, particularly for human cells. In
this study, we report that human Tregs, which we
generated from precursor cells ex vivo, express high
levels of a cell surface protein called PD-L1 (programmed
death ligand-1) that is known to mediate immune
suppression. Coculture of these Tregs with allogeneic
antigen-presenting cells (APCs), which are known to
initiate GVHD, increased, in turn, the amount of PD-L1 on
t h eA P C s .T h eT r e g - c o n d i t i o n e dA P C sw e r et h e nl e s sa b l e
than unconditioned APCs to provoke GVHD in a mouse
model of the condition, preventing the death of the
animals after transplantation. We found that an antibody
against PD-L1 blocked the immunosuppressive effects of
Tregs or Treg-conditioned APCs, indicating that this
protein is an important part of the molecular mecha-
nism. These findings are potentially important for
attempts to modulate immune responses in disease by
transplanting T cells into patients.
Tregs Induce Tolerance via PDL1
PLoS Biology | www.plosbiology.org 2 February 2010 | Volume 8 | Issue 2 | e1000302Figure 1. Tregs express PD-L1 and modulate the PD-1 pathway. (A) Representative flow data for control CD4 cell and Treg expression
of PDL1 ((i) and (ii), respectively). (iii) represents summation of results (mean 6 SEM of n=4 experiments). (B) Control CD4 cells and Tregs
were cocultured with pooled allogeneic DC for2 4h( T r e gt oD Cr a t i o ,1 : 1 )t og e n e r a t e‘ ‘ D C CD4’’ and ‘‘DCTreg’’ populations, respectively.
Control CD4 cells and Tregs were then removed and resultant conditioned DC were evaluated for coexpression of CD80 and PD-L1.
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the PD1 Pathway In Vivo
Next, we utilized an in vivo xenogeneic transplantation model
to further characterize the ability of Tregs or Treg-conditioned
DC to modulate the PD1 pathway. As expected, recipients of
Treg-conditioned DC, which expressed increased PD-L1 in vitro
prior to adoptive transfer, had an increased in vivo number of
dendritic cells in the spleen that expressed PD-L1 (Figure 3A;
representative flow plots (i), (ii), and (iii); summary data, 3b (i));
relative to recipients of control DC, recipients of Treg-conditioned
DC also had an increase in PD-L1–expressing DC in the bone
marrow (p=0.006). Remarkably, recipients of Treg-conditioned
DC also had increased numbers of effector CD4
+ and CD8
+ T
cells in the spleen that expressed PD-L1 in vivo (Figures 3B (ii) and
(iii), respectively); such recipients also had increased numbers of T
cells that expressed PD-L1 in the bone marrow (p=0.003). In
marked contrast, recipients of control CD4-conditioned DC did
not have increased responder T cell PD-L1 expression. Interest-
ingly, recipients of Treg-conditioned DC also had increased
numbers of effector CD8
+ and CD4
+ cells in the spleen that
expressed PD-1 in vivo (Figures 3B (iv) and (v), respectively); in the
bone marrow, such recipients also had increased numbers of
CD8
+PD-1
+ cells (p=0.02) and CD4
+PD-1
+ cells (p=0.009).
Further experiments were performed to assess the functional
significance of this sequential increase in PD-L1 expression from
Treg cell, to conditioned DC, and then to responder T cells in
vivo. Recipients of Treg-conditioned DC that were incubated with
anti–PD-L1 prior to adoptive transfer had lower numbers of PD-
L1–expressing DC in vivo, although cohort comparisons did not
reach statistical significance (Figure 3C (i)); a repeat experiment
yielded similar findings (unpublished data). Blockade of PD-L1 on
Treg-conditioned DC yielded a reduction in the in vivo number of
effector CD8 cells expressing PD-L1 (Figure 3C (ii)). Blockade of
PD-L1 on Treg-conditioned DC also reduced the number of PD-
L1–expressing responder effector CD4
+ cells in the spleen
(Figure 3C (iii)). Finally, PD-L1 blockade of Treg-conditioned
DC reduced the in vivo number of effector CD8
+ cells in the
spleen that expressed PD-1 (Figure 3C (iv)); the number of
CD4
+PD1
+ T cells in the spleen was not significantly altered by
PD-L1 blockade (Figure 3C (v)). In sum, these data indicate that
PD-L1 expression on Treg-conditioned DC was functionally
significant in vivo, particularly with respect to up-regulating
downstream expression of PD1 and PD-L1 on effector CD4
+ and
CD8
+ T cells.
Ex Vivo T Cell Activation Facilitates Human T Cell
Engraftment
Next, we evaluated whether human Treg and Treg-conditioned
DC might modulate xenogeneic GVHD in a PD-L1–dependent
manner. Previous xenogeneic GVHD models have utilized human
peripheral blood mononuclear cells (PBMCs) that contain
unmanipulated human T cells [41,42], or more recently, ex vivo
costimulated T cells [43]. Our initial xenogeneic GVHD
experiments utilized PBMC or purified lymphocytes as the human
T cell inocula. However, despite following the protocol utilized by
previous publications, we found an unacceptably low rate of lethal
GVHD (,10% lethality by day 45 postinfusion); an inability to
consistently generate lethality was associated with a low level of
human T cell engraftment (see Figure S2A). Subsequent
experiments were designed to identify human inocula that yielded
enhanced human T cell engraftment and a resultant increase in
lethal xenogeneic GVHD incidence. An initial experiment found
that engraftment of purified human T cells was enhanced by
coinfusion of a human, but not murine, source of APC
(unpublished data). Based on these data, in a subsequent
experiment, immune-deficient murine hosts received one of five
distinct human T cell–containing inocula: (1) PBMC; (2)
lymphocytes plus monocytes; (3) lymphocytes plus DC; (4) ex
vivo–activated effector T cells plus monocytes; and (5) ex vivo–
activated T cells plus DC. At day 30 postinfusion, recipients of the
ex vivo–activated T cells plus DC had the highest levels of human
CD4
+ and CD8
+ T cell engraftment (Figure S2A (i) and (ii),
respectively); furthermore, recipients of ex vivo–activated T cells
plus DC had the highest capacity for secretion of human IFN-c at
day 30 postinfusion (Figure S2B). Therefore, in order to evaluate
the effects of Tregs, Treg-conditioned DC, and the PD-1 pathway
in a more stringent model of xenogeneic GVHD, subsequent
experiments utilized human inocula that contained ex vivo–
activated T cells and DC.
Tregs or Treg-Conditioned DC Limit Human T Cell
Number and Function In Vivo
Further in vivo experiments were performed to evaluate the
effect of Tregs and Treg-conditioned DC on human T cell
engraftment, cytokine activation, and induction of lethal xenoge-
neic GVHD. Recipients of human inocula that contained either
Tregs or Treg-conditioned DC had reduced absolute numbers of
human T cells as measured in the spleen at day 45 posttransplant
(Figure 4A); the absolute number of human T cells present in vivo
was also reduced when the evaluation was performed in the bone
marrow for recipients of both Tregs (p=0.03) and Treg-
conditioned DC (p=0.01). Tregs and Treg-conditioned DC
transfer resulted in reduced absolute numbers of both human
effector CD8
+ and CD4
+ cells (Figure 4B; representative data (i);
summation of data in (ii) and (iii), respectively). Human CD4
+ T
cell numbers in the bone marrow was also reduced for recipients of
Tregs (p=0.01) but not significantly reduced in recipients of Treg-
conditioned DC (p=0.08); human CD8
+ T cell numbers in the
Representative data for DCCD4 and DCTreg conditions are shown in (i) and (ii), respectively. (iii) represents summation of results (mean 6 SEM
of n=5 experiments). (C) Flow cytometry detection of the PD-L1 binding partners PD1 and CD80 on effector CD4
+ cells ((i), (ii), and (iii)) and
CD8
+ cells ((iv), (v), and (vi)) after exposure to control or conditioned allogeneic DC for 48 h. Representative histograms showing isotype
control (i) and PD1 staining of CD4 effectors (ii); (iii) represents summation of CD4 cell results (mean 6 SEM of n=3 experiments). Similarly,
representative histograms showing isotype control (iv) and PD1 expression of CD8 effectors (v); (vi) represents summation of CD8 cell results
(mean 6 SEM of n=3 experiments). (D) Laser scanning cytometry for detection of PD-L1 binding partners on both CD4+ and CD8+ responder
T cells. Enriched responders were incubated with a PD-L1 fusion protein. Pseudocolor and fluorescence images of PD-L1 binding to responder
T cells stimulated with control CD4 cell–conditioned DC are shown in (i) and (ii), respectively; pseudocolor and fluorescence images of PD-L1
binding to responder T cells stimulated with Treg-conditioned DC are shown in (iii) and (iv), respectively. Blocking studies were performed to
determine PD-L1 receptor usage: enriched responders were blocked with anti-PD1 or anti-CD80 and then incubated with PD-L1 fusion
protein (v). (E) Responder T cell binding of PD-L1 fusion protein by flow cytometry. Allo-MLR was established using control CD4- or Treg-
conditioned DC. After 48 h, responder T cells were harvested, stained with PD-L1 fusion protein, and flow cytometry was performed.
Representative flow histograms show responder T cell PD-L1 binding using control CD4-conditioned DC (i) or Treg-conditioned DC (ii). Pooled
results from n=3 normal donors are shown in (iii) (% of cells binding PDL-1; mean 6 SEM); (iv) shows blocking studies for n=3 donors in an
independent experiment (% of cells binding PD-L1; mean 6 SEM).
doi:10.1371/journal.pbio.1000302.g001
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but not significantly reduced in recipients of Treg-conditioned DC
(p=0.09). Of note, recipients of Tregs, but not recipients of Treg-
conditioned DC, had a statistically significant reduction in the
absolute number of posttransplant CD8
+Tc1 and CD4
+Th1 cells
capable of IFN-c secretion (Figure 4C (i) and (ii), representative
flow plots; 4C (iii) and (iv), summation of data). In sum, these data
indicated that both Treg cells and Treg-conditioned DC were
capable of inhibiting human T cells in vivo, with Treg therapy
manifesting more potent regulation both in terms of limiting T cell
numbers and T cell effector function.
Tregs or Treg-Conditioned DC Protect against Lethal
Xenogeneic GVHD
Xenogeneic GVHD was evaluated by weight loss measurement,
survival analysis, and histology evaluation of GVHD target tissues.
Recipients of Tregs or Treg-conditioned DC were uniformly
protected against lethal xenogeneic GVHD (Figure 5A (i));
importantly, recipients of control CD4-conditioned DC uniformly
died of xenogeneic GVHD. Posttransplant weight loss, which is a
more sensitive clinical parameter of xenogeneic GVHD, was
moderated by Treg-conditioned DC therapy and virtually
eliminated by Treg therapy (Figure 5A (ii)). In a second
experiment, we confirmed the ability of Treg-conditioned DC to
completely abrogate the generation of lethal xenogeneic GVHD;
importantly, protection against lethal xenogeneic GVHD con-
ferred by the Treg-conditioned DC was completely abrogated by
anti–PD-L1, but not by isotype control antibody (Figure 5B). Of
note, both control DC and Treg-conditioned DC engrafted and
persisted in vivo; importantly, such numbers were not substantially
influenced by Treg therapy or anti-PDL1 antibody. That is, at day
25 posttransplant, the absolute numbers of CD11c
+ DC per spleen
(each value, 610
3; n=5 per cohort) in transplant recipients that
Figure 2. Treg-conditioned DC have reduced allostimulatory function in part through PD-L1. (A) Experimental schema for the allo-MLR
using Treg-conditioned DC. Control CD4 cells or Tregs were generated ex vivo and then utilized to condition allogeneic DC (24-h incubation; 1:1 cell
ratio). Conditioned DC were then purified by negative selection using anti-CD3 microbeads and utilized as the stimulator population (DC to
responder T cell ratio, 1:20). The allo-MLR was performed in the presence of anti-PD-L1 or isotype control antibody. (B) Representative CFSE dye
dilution proliferation assay results, including responder CD4 alloreactivity in response to: unmodified DC (i); DC conditioned with Tregs either without
(ii) or with (iii) addition of anti–PD-L1; and DC conditioned with control CD4 cells either without (iv) or with (v) anti–PD-L1. (C) Percent inhibitiono f
responder CD4 cell proliferation (i) and responder CD8 cell proliferation (ii) were calculated relative to proliferation measured using sham-treated DC.
Results are mean 6 SEM of n=8 normal donors evaluated.
doi:10.1371/journal.pbio.1000302.g002
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PLoS Biology | www.plosbiology.org 5 February 2010 | Volume 8 | Issue 2 | e1000302Figure 3. Treg-conditioned DC modulate effector T cells in vivo via PD-L1. A xenogeneic transplantation model utilized Rag2
2/2cc
2/2 mice
that received some combination of human cells, as indicated, including: CFSE-labeled effector Teff cells (‘‘Teff’’); untreated DC (‘‘DC’’), control CD4-
conditioned DC (‘‘DCCD4’’), or Treg-conditioned DC (‘‘DCTreg’’); and ex vivo–generated control CD4 cells (‘‘CD4’’) or regulatory T cells (‘‘Treg’’). (A)
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specific type of human DC were 136611 (control DC), 10766
(control DC and Treg therapy), 418698 (Treg-conditioned DC),
163663 (Treg-conditioned DC, anti–PDL1-treated), and 279677
(Treg-conditioned DC, isotype antibody treated) (each compari-
son, p=NS by ANOVA test). GVHD control mice uniformly
developed a diffuse skin rash and hair loss; skin histology analysis
documented cutaneous acanthosis and hyperkeratosis in GVHD
controls, but not in Treg recipients (representative histology;
Figure 5C (iii) and (iv), respectively). Furthermore, GVHD
controls, but not Treg recipients, developed diffuse lymphocytic
infiltration of the liver (representative histology; Figure 5C (i) and
(ii), respectively).
Discussion
The rational design of adoptive cell therapy protocols using ex
vivo–expanded Tregs would be facilitated by an improved
understanding of their cellular and molecular mechanism of
action, which has been difficult to ascertain, particularly with
respect to human Tregs. In this report, utilizing a novel method of
generating human Tregs based on CD127 negative selection, we
have elucidated a unique Treg mechanism of immune suppression
analogous to previously described models of infectious tolerance
[44] that is mediated at least in part by modulation of allogeneic
dendritic cells through the PD-L1 pathway. This mechanistic
understanding is particularly pertinent to efforts that will utilize
Tregs for the prevention or treatment of GVHD, which is driven
by allogeneic DC [30] and is amenable to suppression through
PD-1 [45].
Our results are the first, to our knowledge, to describe a
mechanism of human Treg action that involves potent in vitro and
in vivo suppression of effector T cells through a secondary cellular
messenger, myeloid dendritic cells. A similar biology has been
described in murine models, whereby Tregs create a weak
stimulator DC through induction of immunosuppressive indolea-
mine 2,3-dioxygenase (IDO) via a CTLA-4– or IFN-c–dependent
pathway [26]. Interestingly, the reverse biology has also been
described in murine models, whereby murine plasmacytoid DC
that produce IDO promote the generation of immunosuppressive
Tregs that express PD-L1 [24]. Of note, in our experiments,
inhibition of IDO by 1-MT treatment did not abrogate
suppression mediated by Treg-conditioned myeloid DC (unpub-
lished data). Similar to a previous study using freshly isolated
human Tregs [29], we found that ex vivo–generated human Tregs
inhibited myeloid DC secretion of the proinflammatory cytokines
IL-6 and TNF-a (unpublished data) and induced a DC phenotype
with greatly reduced capacity to induce responder T cell
proliferation in vitro. Most importantly, we have significantly
extended this prior work through our discovery that myeloid DC
conditioned by Tregs were effective in vivo for the complete
elimination of posttransplant lethal xenogeneic GVHD induced by
effector T cells. In addition to this apparent DC-mediated
mechanism of GVHD protection, other non-APC mechanisms
are likely operative for the Tregs that we studied, because
transplant cohorts that received Tregs had more robust protection
against xenogeneic GVHD than recipients of Treg-conditioned
DC (lowest CD4
+ and CD8
+ T cell engraftment, lowest
posttransplant IFN-c secretion, and lowest degree of weight loss
posttransplant).
Furthermore, this is the first demonstration that human Tregs
mediate immune suppression in vivo through modulation of the
PD-1 pathway. First, we observed that ex vivo–expanded human
Tregs expressed increased PD-L1 relative to control expanded
CD4
+ T cells. Second, Treg-conditioned DC expressed greatly
increased PD-L1 relative to DC conditioned with control CD4
cells. As such, Treg PD-L1 appeared to directly induce DC PD-L1
expression; the potential existence of such a PD-L1 ‘‘positive
feedback loop’’ adds to the known complexity of PD-1 pathway
regulation [36] and to our knowledge has not been previously
described for murine or human Tregs. Third, this feedback
appeared to extend to the distal stage of effector T cell regulation
because effector CD4
+ and CD8
+ cells under the influence of
Treg-conditioned DC, but not control CD4-conditioned DC, had
nearly universal expression of PD-L1 binding partners. Finally, we
determined that such effector T cell binding to PD-L1 was
preferentially mediated through PD-1 rather than the other
receptor associated with this pathway, CD80. It is interesting to
note that a recent study found that PD-1 expression on Treg cells
in patients with viral hepatitis played a negative regulatory role for
Treg cell function via limitation of STAT-5 phosphorylation [46].
In our experiments, the ex vivo–activated Treg cells expressed a
high level of PD-1, yet were able to mediate potent suppression of
effector T cells in vivo at relatively dilute Treg to effector T cell
ratio; as such, it does not appear that the PD-1 pathway exerted a
functionally significant down-regulatory effect on the Tregs
utilized in our model. It is interesting to note that the Treg-
conditioned DC did not express significant PD-1; it is thus possible
that the capacity of this cell population to effectively prevent
xenogeneic GVHD may reside in part on a limited susceptibility to
PD-1–mediated suppression.
Importantly, this biology was functional in vivo because: (1)
Treg-conditioned DC maintained expression of PD-L1 after
adoptive transfer; (2) effector (Teff) cells up-regulated both PD-
L1 and PD1 in vivo in the presence of Treg-conditioned DC; and
(3) a significant proportion of this immune modulation was
abrogated if Treg-conditioned DC were blocked with anti–PD-L1.
Remarkably, the survival advantage conferred by Treg-condi-
tioned DC was fully abrogated by anti–PD-L1. In sum, these data
demonstrate that modulation of the PD-1 pathway represents a
significant mechanism of action of ex vivo–expanded Tregs that
involves an interaction between Tregs, DC, and effector T cells in
an apparent positive feedback loop. Further experiments will be
required to better understand this process of intercellular PD-1
pathway modulation. Potentially, the PD-L1 suppressor phenotype
might be transferred from Tregs to DC and then to effector T cells
by a process of trogocytosis [47], which results in the generalized
transfer of cell membrane proteins, including costimulatory
Spleens were harvested 24 h after cell infusion and analyzed by flow cytometry. Human cells were gated by human CD45
+ staining including any
human CD3
+ T cells (representative data; (i)). PDL1 expression was evaluated on DC by CD11c staining (representative data, (ii)); PD1 expression was
evaluated on CD4 cells (representative data, (iii)). (B) Flow cytometric analysis was used to measure the absolute number of: CD11c
+ DC that
coexpressed PD-L1 (i); CD8
+ and CD4
+ T cells that coexpressed PD-L1 ((ii) and (iii), respectively); and CD8
+ and CD4
+ T cells that coexpressed PD-1 ((iv)
and (v), respectively). Results are mean 6 SEM of n=5 mice per cohort. (C) In a separate experiment, control CD4-conditioned or Treg-conditioned DC
were incubated for 30 min with anti–PD-L1 or isotype control antibody prior to adoptive transfer; in addition, anti–PD-L1 or isotype control antibody
was injected intraperitoneally immediately after cell transfer (100 mg/mouse). Spleens were harvested 24 h after cell infusion and analyzed by flow
cytometry to determine the absolute number of: CD11c
+ DC that coexpressed PD-L1 (i); CD8
+ and CD4
+ T cells that coexpressed PD-L1 ((ii) and (iii),
respectively); and CD8
+ and CD4
+ T cells that coexpressed PD-1 ((iv) and (v), respectively). Results are mean 6 SEM of n=5 mice per cohort.
doi:10.1371/journal.pbio.1000302.g003
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PLoS Biology | www.plosbiology.org 7 February 2010 | Volume 8 | Issue 2 | e1000302Figure 4. Reduction in human effector T cell numbers in vivo by Tregs or Treg-conditioned DC. Rag2
2/2cc
2/2 mice were reconstituted
with human cells, as indicated, including: effector Th1/Tc1 cells (‘‘Teff’’); untreated DC (‘‘DC’’) or Treg-conditioned DC (‘‘DCTreg’’); and ex vivo–
generated control CD4 cells (‘‘CD4’’) or regulatory T cells (‘‘Treg’’). Teff, DC, and Treg doses were 1610
7, 0.5610
6, and 0.5610
6 cells per recipient,
respectively. One additional cohort received Teff cells in combination with control CD4-conditioned DC; this cohort is not shown because of early
posttransplant lethality due to xenogeneic GVHD. (A) Spleens were harvested on day 45 posttransplant and percent human cell engraftment was
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regulated DC expression of PD-L1, but not other cell surface
molecules such as PD-1, we speculate that alternative mechanisms
of intercellular regulation may be operational.
These findings have several implications for ongoing efforts to
utilize ex vivo–generated Tregs for adoptive cell therapy. First, we
have found that CD127
2 selection represents a suitable alternative
to CD25
+ selection for attempts to enrich for Tregs prior to ex vivo
expansion; further experiments will be required to directly
compare these two methodologies to determine whether such
methods result in differential modulation of APC function through
the PD-1 pathway. It is perhaps important to emphasize that the
regulatory T cell or Treg-conditioned DC modulation of
xenogeneic GVHD was robust because it occurred at the relatively
low regulatory cell to effector cell ratio of 1:20, which is considered
to represent a physiologic ratio. Second, our demonstration that ex
vivo–generated Tregs operate to a significant degree indirectly
through allogeneic myeloid DC may help guide protocol design,
particularly in the setting of allogeneic HSCT. One theoretical
limitation to Treg cell therapy is the transfer of ‘‘contaminating’’
effector T cells or the conversion of Tregs to proinflammatory
Th17 cells [49] that are known to induce GVHD [10]. The APC
mechanism we have identified offers a solution to this potential
limitation: that is, one could harvest host-type monocytes
pretransplant and generate myeloid DC in a manner similar to
the methods that we utilized, condition such DC with ex vivo–
generated Tregs, and then transfer only the conditioned host DC
prior to allogeneic HSCT. Such an approach would be analogous
to that proposed for type II DC (DC2 cells) that promote Th2
cytokines and prevent murine GVHD [50]. Our results also
indicate that the capacity of adoptively transferred Tregs to
modulate GVHD may relate in part to the bioavailability of host-
type myeloid DC. This consideration may have relevance to the
choice of host conditioning for Treg protocols: predictably, non-
myeloablative regimens may be favorable in this regard because
such regimens would preserve host myeloid DC as a key secondary
cellular mediator of the Treg therapy.
It should be stated that xenogeneic models of GVHD likely do
not fully reflect the biology of clinical GVHD, and as such, the
potential clinical implications of the findings in our model must be
interpreted with caution. Specifically, the xenogeneic transplanta-
tion model that we utilized did not incorporate a human
hematopoietic stem cell component, and as such, the potential
effect of the regulatory T cells or Treg-conditioned DC that we
evaluated on stem cell engraftment was not assessed. However, we
found that human dendritic cell and effector T cell engraftment
was persistent at the relatively late time points of day 25 and day
45 posttransplant, respectively; thus, it is possible that human
hematopoietic progenitor cell engraftment would also be durable
under the conditions that we evaluated. Such a possibility would
be consistent with data emanating from murine models of MHC-
disparate transplantation, which have found Treg adoptive
transfer to augment allogeneic hematopoietic stem cell engraft-
ment [7,51]. Our findings relating to PD-1 pathway modulation
may also hold clinical implications. Adoptive cell therapy using
Tregs or Treg-conditioned DC may be conceptualized as a vehicle
for PD-L1 delivery. Such a cell therapy approach may have
immediate practical benefit for the treatment of the myriad of
diseases that may benefit from PD-1 agonism [52]. That is,
although an antibody-based method of PD-1 antagonism has
already been investigated in phase I clinical trials [53], it is unclear
whether agonistic PD-1 antibodies will be available or safely
administered. Finally, the mechanisms we have identified will
provide a rationale for monitoring PD-1 and PD-L1 expression on
posttransplant T cells and DC as a biological marker for in vivo
activity of the administered Tregs or Treg-conditioned DC; in
addition, surface PD-L1 expression may be utilized as a marker to
facilitate a functionally defined release criteria for the experimental
cell therapy products.
In conclusion, ex vivo expansion of CD127-negatively selected
CD4
+ T cells yielded a human Treg product that inhibited
alloreactivity in vitro and in vivo, in large part due to modulation
of myeloid DC and a multifaceted promotion of the PD-1
pathway in Tregs, DC, and effector T cells. As such, we have
identified two distinct cell therapy vehicles, Tregs and Treg-
conditioned myeloid DC, each of which show promises as a novel
approach to modulate human effector T cells through the PD-1
pathway.
Materials and Methods
Mice
Female RAG2
2/2cc
2/2 mice were obtained from Taconic and
utilized at 8–12 wk of age. Experiments were performed according
to a protocol approved by the National Cancer Institute Animal
Care and Use Committee. Mice were housed in a sterile facility
and received sterile water and pellets. As in previously reported
methods [31,41], mice were injected with 0.1 ml of chlodronate-
containing liposomes (Encapsula Nanoscience) for macrophage
depletion and given low-dose irradiation (350 cGy).
Antibodies and Reagents
X-VIVO 20 media was obtained from BioWhitaker and AB
serum was from Gem Cell. CD4 microbeads were from Miltenyi
Biotec. Sheep anti-mouse (SAM) IgG dynabeads were from Dynal.
Anti-CD3, anti-CD28 coated tosyl-activated magnetic beads were
manufactured as previously described [54]. Rapamycin was from
Wyeth (Rapamune). Recombinant human (rh) IL-2 and rhIL-12
were from PeproTech, and rhTGF-b1, aTGF-b1, -b2, -b3, and
purified aPD-L1 were from R&D Systems. All other antibodies
(unless otherwise stated) were provided by BD Biosciences; anti-
human Foxp3 APC was from eBioscience. Luminex kits for
detection of IFN-c and TNF-a were from Bio-Rad. 5-(and-6)-
Carboxyfluorescein diacetate, succinimidyl ester [5(6)-CFDA, SE;
CFSE] was from Invitrogen.
T Cell Subset Isolation
Normal donor peripheral blood cells were collected by apheresis
on an IRB-approved protocol. Total lymphocytes were isolated by
elutriation [55]. Total CD4
+ T cells were then enriched by CD4
microbeads according to manufacturer instructions. To isolate
CD127-depleted CD4
+ T cells: (1) elutriated lymphocytes were
adjusted to 100610
6 cells/ml and incubated with anti-CD127
(10 mg/ml, 30 min, 4uC); (2) cells were washed, mixed with SAM
determined by flow cytometry. (B) Representative flow data of human CD4
+ and CD8
+ T cell engraftment (i). Summation data for the absolute
number of human CD8
+ T cells engrafted in the spleen (ii) and human CD4
+ T cells engrafted in the spleen (iii). (C) At day 45 posttransplant,
splenocytes were costimulated for 24 h, and IC flow cytometry was performed to detect human CD4
+ and CD8
+ T cells capable of IFN-c secretion.
Representative flow results are shown in (i) and (ii). Summation results for determination of the absolute number of human CD4
+IFN-c
+ cells and
CD8
+IFN-c
+ cells per spleen are shown in (iii) and (iv), respectively. All results are mean 6 SEM for n=5 mice per cohort.
doi:10.1371/journal.pbio.1000302.g004
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separated (hand-held magnet, Dynal); and (3) CD127-depleted
cells were subjected to CD4 cell isolation by microbeads.
Ex Vivo Culture of Total CD4
+ and CD4
+CD127
2 T Cell
Subsets
Total CD4
+ and CD4
+CD127
2 T cells were cultured in
polystyrene tissue culture flasks (Corning). Cells were activated
by anti-CD3, anti-CD28 costimulation (bead:cell ratio, 3:1), and
cultured in X-VIVO 20 with 5% heat-inactivated (HI) AB
serum containing rapamycin (1 mM), TGF-b1 (20 ng/ml), rhIL-
2 (100 IU/ml). rhIL-2 alone was added at days 2, 4, and 6.
Cultures were started at 1.5610
6 cells/ml, maintained at 1610
6
cells/ml through day 7, and then split daily to 0.5610
6/ml
by addition of IL-2 and rapamycin-replete medium through
day 12.
Figure 5. Tregs or Treg-conditioned DC protect against lethal xenogeneic GVHD. Using Rag2
2/2cc
2/2 mice as host, transplant cohorts
received effector T cells (‘‘Teff’’) in combination with allogeneic DC, control CD4 cell-conditioned DC (‘‘DCCD4’’), or Treg-conditioned DC (‘‘DCTreg’’);
other cohorts received Teff cells in combination with allogeneic DC plus either Tregs (‘‘Treg’’) or control CD4 cells (‘‘CD4’’). The doses of the Teff, DC,
and Treg cells were 3610
7, 3.0610
6, and 1.5610
6 cells per recipient, respectively. (A) Overall survival is shown in (i); posttransplant weight loss is
shown in (ii). (B) In an independent experiment, transplants were performed at these same cell doses, and posttransplant survival was determined.
Treg-conditioned DC were incubated with anti–PD-L1 (‘‘aPDL1’’) or isotype control antibody (‘‘mIgG2a’’) for 30 min prior to adoptive transfer; in
addition, anti–PD-L1 or isotype control antibody was injected i.p. immediately after cell transfer (100 mg/mouse). (C) Representative result of
histology analysis performed at day 30 posttransplant demonstrates T cell infiltration of liver in the GVHD control group (i) and minimal infiltration in
recipients of Tregs (ii). Representative histology of skin demonstrates cutaneous acanthosis and hyperkeratosis in GVHD controls (iii) and minimal skin
pathology in recipients of Tregs (iv).
doi:10.1371/journal.pbio.1000302.g005
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T cells were washed with PBS supplemented with 0.1% BSA
and 0.01% azide, and stained using anti-: CD4 PE-cy7 (clone
S3.5; Caltag), Foxp3 APC (clone 249D; eBioscience), CCR7 PE
(clone 150503; R&D), CTLA-4 Biotin (clone BN13), CD27 FITC
(clone M-T271), and CD62L APC-cy7 (clone DREG-56;
Biolegend). For intracellular (IC) flow cytometry, fixation and
permeabilization buffer was utilized (eBioscience); four-color IC
flow cytometry was performed with combinations of anti-: IL-2
biotin (clone B33-2), IFN-c APC (clone B27), CD4 Pe-Cy5 (clone
RPA-T4), and Foxp3 PE (clone PCH101; eBioscience). DC were
evaluated using anti-: CD80 Bio (clone L307.4), CD86 APC (clone
2331), CD14 PE (clone M5E2), CD83 FITC (clone HB15e),
CD40 APC (clone 5C3), and PDL1 PE-cy7 (clone MIH1).
Generation of Myeloid DC
Monocytes from four healthy, randomly selected donors were
obtained by apheresis and elutriation; HLA typing confirmed that
the donors did not share major haplotypes. Each monocyte
population was cultured in X-VIVO 20 medium with 5% HI-AB
serum, rhGM-CSF (50 ng/ml), and rhIL-4 (20 ng/ml). On day 5,
each DC culture was enumerated and subjected to flow cytometry
to document a DC phenotype (CD14
2, CD11c
+, CD83
+, CD80
+,
CD86
+; unpublished data). The four separate DC populations
were pooled in equal proportions, and aliquots of the final product
were cryopreserved and utilized for each experiment.
Allogeneic Mixed Lymphocyte Reaction (MLR)
Normal donor lymphocytes (‘‘responder T cells’’; 2610
5 cells)
were cocultured with allogeneic DC (5610
4 cells) in 96-well round-
bottom plates (T cell to DC ratio, 20:1). To detect proliferation,
responder T cells were CFSE-labeled before coculture. From the
same normal donors, Tregs were generated from CD4
+CD127
2
cells, or as a control, from total CD4
+ cells. Initial experiments
determined that a Treg to responder T cell ratio of 1:20
consistently yielded suppression of proliferation. Proliferation of
CD4
+ and CD8
+ responder T cells was evaluated by CFSE dye
dilution; percent suppression of CD4 and CD8 responder T cell
suppression was calculated, with values representing the ratio of
total divided peaks to both divided and nondivided peaks,
normalized to the sham-treated experimental group.
Mechanistic Assays Relating to the MLR
During the MLR, neutralizing antibodies were added, including
anti-: CTLA-4, IL-10, TGF-b1, TGF-b2, TGF-b3, LAP, and their
respective isotope controls. All antibodies were used at 20 mg/ml.
A combination of anti-CTLA-4, anti-TGF-b, and anti-LAP was
also tested. 1-methyl-D-tryptophan (1-MT, 1 mM; Sigma) was
utilized to inhibit indoleamine 2,3-dioxygenase (IDO). Transwell
plates with a 4-mm membrane (Corning LifeSciences) were
utilized to assess Treg contact dependency.
Isolation of Treg-Conditioned Dendritic Cells
For the secondary transfer experiments, DC were incubated
with Tregs for 48 h (Treg to DC ratio, 1:1). Tregs were then
removed using T cell–positive selection (anti-CD3 microbeads and
subsequent magnetic column separation; Miltenyi); the resultant
population was .99% pure for DC content, as determined by flow
cytometry using CD11c in combination with CD80, CD86, and
CD40. Such Treg-conditioned DC were then used as stimulator
cells, with degree of proliferation determined relative to DC
conditioned with control T cells (cells generated ex vivo from total
CD4 cells) or sham-treated DC. MLR assays using preconditioned
DC were also performed with anti–PD-L1 (20 mg/ml) or isotype
control antibody.
Laser Scanning Cytometry
On day 5, responder T cells were evaluated for expression of
PD-L1 binding partners PD1 and CD80. The responder T cells
were blocked with a specific aPD1 (1 mg/1610
6 cells) and aCD80
(1 mg/1610
6 cells) antibody and then PD-L1 binding was studied
by incubation with recombinant PD-L1-Fc fusion molecule
(R&D); secondary incubation was performed with FITC-labeled
rabbit anti-human IgG, Fc-fragment antibody (Jackson Laborato-
ry). Stained T cells were delivered to 96-well plates with a plastic
#1 cover slip bottom (1610
5 cells in 200 ml) and analyzed (iCys
Laser Scanning Cytometer; Compucyte Corporation). Cells were
scanned (488-nm laser) and fluorescence was detected (530/30-nm
band-pass filter). Scan images and fluorescence data were
generated (iGeneration and innovator software; Compucyte).
Images were collected at 0.5-mm scan resolution.
Xenogeneic GVHD Model
Human effector CD4
+Th1/CD8
+Tc1 (Teff) cells were gener-
ated by T cell culture for 6 d by costimulation and expansion of T
cells in rhIL2 (20 IU), aIL-4 (100 ng/ml), rhIL-12 (20 ng/ml), and
rapamycin (1 mM). On day 6 of culture, Teff cells were harvested
and injected (i.v. by retro-orbital method, as previously described
[43]) into Rag2
2/2cc
2/2 mice conditioned with chlodronate and
radiation; Teff cell dose was either 1 or 3610
7 cells/recipient
(higher dose used for evaluation of posttransplant lethality).
Specific cohorts additionally received ex vivo–generated Tregs
(generated from CD4
+CD127
2 cells) or control T cells (generated
from total CD4 cells) at a dose of 0.5 or 1.5610
6 cells/recipient
such that the in vivo ratio of effector Teff cells to Tregs always
matched that utilized in the allogeneic MLR (20:1). As indicated,
cohorts additionally received pooled allogeneic DC (complete
mismatch as compared to Teff and Tregs) utilized in the MLR
(DC dose, 0.5 or 1.5610
6 cells/recipient) to maintain constant
ratios; allogeneic DC were either not conditioned or conditioned
with ex vivo–generated Tregs or control T cells. For blocking
experiments, conditioned DC were incubated with anti-PD-L1
(20 mg/ml) or isotype control antibody prior to adoptive transfer.
In some cases, anti-PD-L1 was injected following cell transfer (i.p.;
100 mg/recipient). After adoptive transfer, human engraftment
was calculated using flow cytometry data from splenic single-cell
suspensions (% huCD45
+=[huCD45
+ (huCD45
++ mCD45
+)]6
100%). Surface or intracellular flow cytometry was performed at
indicated days after adoptive transfer to assess in vivo modulation
of responder human CD4 and CD8 T cells and human DC.
Statistical Analysis
Flow cytometry and cytokine data were analyzed using Student
2-tailed t-tests. Comparison values of p,0.05 were considered
statistically significant. Survival was determined using Kaplan-
Meier test. For three pairwise cohort comparisons, statistical
analyses was performed using the Holm method [56].
Supporting Information
Figure S1 Ex vivo T cell expansion and day 12
phenotype. Ex vivo costimulation and expansion in medium
containing IL-2, rapamycin, and TGF-b was performed on total
bulk CD4
+ input cells or CD4
+CD127
2 input cells to generate
control CD4 cells (‘‘bulk CD4’’) and regulatory T cells (‘‘Treg’’),
respectively (results from n=8 normal donors). (A) Fold-expansion
from day 0 to day 12 of culture. (B) At day 12, cells were evaluated
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(B) (ii). (C) Bulk CD4 cells and Tregs were restimulated for 24 h,
and IC flow cytometry was performed to evaluate effector T cell
coexpression of Foxp3 and IL-2 (i) or IFN-c (ii). Results are
mean 6 SEM of n=5 cultures. (D) Control CD4 cells and Tregs
were compared for ability to suppress CD4
+ (i) and CD8
+ (ii) T cell
proliferation over 5 d of culture in response to allogeneic DC
(mean 6 standard error of the mean [SEM] of n=8 donors). (E)
Representative data showing control CD4 and Treg suppression of
responder CD4 (i) and CD8 (ii) proliferation over a range of
suppressor cell to target ratios of 1:20 to 1:100.
Found at: doi:10.1371/journal.pbio.1000302.s001 (0.22 MB TIF)
Figure S2 Human T cell numbers in vivo: role of ex vivo
T cell activation. Rag2
2/2cc
2/2 mice were reconstituted with
human cells, as indicated, including: PBMC alone (‘‘PBMC’’),
purified lymphocytes plus either monocytes (‘‘Lymph+mono’’) or
DC (‘‘Lymph+DC’’), or ex vivo-expanded effector T cells alone
plus either monocytes (‘‘Teff+mono’’) or DC (‘‘Teff+DC’’). The
dose of effector T cells and APC populations were 1610
7 and
0.5610
6 cells per recipient, respectively. (A) On day 30 after
transplant, the number of human CD4
+ and CD8
+ T cells in the
spleen was determined using flow cytometry ((i) and (ii),
respectively). (B) At day 30 posttransplant, splenic cells were
costimulated using anti-human CD3 and CD28 beads; the
resultant 24-h supernatant was then tested for content of IFN-c
by multiplex bead array. All results shown are the mean 6 SEM of
n=10 recipients per cohort. An asterisk (*) indicates that the
difference relative to the PBMC cohort was statistically significant
(p,0.05).
Found at: doi:10.1371/journal.pbio.1000302.s002 (0.14 MB TIF)
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